JLE

Hématologie

MENU

Est-il possible d’élargir les indications du CPX-351 aux leucémies aiguës lymphoblastiques à haut risque de mortalité en induction ? Volume 26, issue 6, Décembre 2020

  • [1] Lim W.-S., Tardi P.G., Dos Santos N. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34:1214-1223.
  • [2] Lancet J.E., Uy G.L., Cortes J.E. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684-2692.
  • [3] Issa G.C., Kantarjian H.M., Xiao L. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020;34:2914-2924.
  • [4] Kantarjian H., O’brien S., Cortes J. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098.
  • [5] DiNardo C.D., Jonas B.A., Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.